ACM
DYN icon

Altium Capital Management’s Dyne Therapeutics DYN Stock Holding History

Altium Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-315,000
Closed -$2.82M – 74
2023
Q3 		$2.82M Buy
315,000
+160,000
+103% +$1.72M 1.47% 22
2023
Q2 		$1.74M Hold
155,000
– – 1.32% 24
2023
Q1 		$1.79M Buy
+155,000
New +$2.01M 0.99% 38
2022
Q1 		– Sell
-166,636
Closed -$1.98M – 128
2021
Q4 		$1.98M Hold
166,636
– – 0.55% 66
2021
Q3 		$2.71M Hold
166,636
– – 0.71% 60
2021
Q2 		$3.51M Hold
166,636
– – 0.81% 49
2021
Q1 		$2.59M Buy
+166,636
New +$3.22M 0.72% 57

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Altium Capital Management's DYN Position: Q4 2023 in Review

Altium Capital Management sold out of Dyne Therapeutics (DYN) in Q4 2023, closing a stake of 315,000 shares — an estimated $2.82M sold.

Altium Capital Management first reported a position in DYN in Q1 2021 and held it in 7 quarters. The position peaked at $3.51M in Q2 2021. 124 funds tracked by Wall St. Rank hold DYN as of Q4 2023.

  • Altium Capital Management reported no remaining Dyne Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Altium Capital Management sold 315,000 Dyne Therapeutics shares in Q4 2023, an estimated $2.82M.
  • Altium Capital Management first reported a position in Dyne Therapeutics in Q1 2021 and held it in 7 quarters.
  • Altium Capital Management's Dyne Therapeutics position peaked at $3.51M in Q2 2021.
  • 124 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2023.

Based on Altium Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.